Effect of alphapinen addition to pharmacotherapy regimen of ulcerative colitis patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20121021011192N17

Enrollment

Registered

2024-06-01

Start date

2024-06-21

Completion date

Unknown

Last updated

2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ptients with diagnosis of ulcerative colitis. Ulcerative colitis, unspecified

Interventions

Intervention 1: Intervention group: addition of alphapinen 30 mg per day orally to the ulcerative colitis regimen for 8 weeks. Intervention 2: Control group: addition of alphapinen capsule placebo dai

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients with diagnosis of ulcerative colitis on the basis of doing colonpscopy Obtaining written informed consent

Exclusion criteria

Exclusion criteria: Patients with previous history of allergy to alphapinen

Design outcomes

Primary

Measure	Time frame
Relief in laboratory index CRP. Timepoint: 8 weeks after finishing drugs. Method of measurement: assessment of blood CRP.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Abbasinazari

Shahid Beheshti University of Medical Sciences

m_abbasi@sbmu.ac.ir+98 21 8887 3704

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026